Drug
Tetrathiomolybdate clinical trials
Also written ALXN1840, Tiomolibdate choline and WTX101.
Keep track of what changes. Save the tetrathiomolybdate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
29 studies that test it; most in 2020 (6)
| Year | Studies |
|---|---|
| 1994 | 1 |
| 2001 | 3 |
| 2003 | 2 |
| 2004 | 1 |
| 2006 | 4 |
| 2007 | 1 |
| 2008 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 13
Alexion Pharmaceuticals, Inc. (14) · University of Michigan Rogel Cancer Center (3) · Attenuon (3) · University of Michigan (2) · National Center for Research Resources (NCRR) (2) · University of Rochester (1) · George Brewer (1) · Dartmouth-Hitchcock Medical Center (1)
Often tested with
Tested in the same studies.
Omeprazole (2) · Moxifloxacin (1) · Irinotecan (1) · Fluorouracil (1) · Leucovorin (1) · Exemestane (1) · Bortezomib (1) · Temozolomide (1)
Studies
Open first, then newest update. How each study uses tetrathiomolybdate is read from its arms, and is right about nine times in ten.
Testing it · 30
- A Study of Tetrathiomolybdate (TM) Plus CapecitabineRecruitingPhase 1/2Dartmouth-Hitchcock Medical CenterNCT06134375Written as Tetrathiomolybdate
- Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast CancerTerminatedPhase 2Memorial Sloan Kettering Cancer CenterNCT00195091Written as Tetrathiomolybdate
- Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson DiseaseTerminatedPhase 3Alexion Pharmaceuticals, Inc.NCT05047523Written as ALXN1840
- Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840CompletedPhase 2Alexion Pharmaceuticals, Inc.NCT04422431Written as Bis-Choline Tetrathiomolybdate
- Copper Balance in Healthy Participants Administered ALXN1840CompletedPhase 1Alexion Pharmaceuticals, Inc.NCT04594252Written as ALXN1840
- Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840CompletedPhase 2Alexion Pharmaceuticals, Inc.NCT04573309Written as ALXN1840
- Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson DiseaseTerminatedPhase 3Alexion Pharmaceuticals, Inc.NCT03403205Written as ALXN1840
- Bioavailability Study of 2 Oral Formulations of ALXN1840CompletedPhase 1Alexion Pharmaceuticals, Inc.NCT04610580Written as ALXN1840
- Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy ParticipantsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT05641311Written as ALXN1840
- Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy ParticipantsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT04526210Written as ALXN1840
- Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.CompletedPhase 1Alexion Pharmaceuticals, Inc.NCT04526197Written as ALXN1840
- A Study of the Cardiac Effects of ALXN1840 in Healthy AdultsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT04560816Written as ALXN1840
- Study of Oral ALXN1840 at 2 Dose Strengths in Healthy AdultsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT05303324Written as ALXN1840
- A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy AdultsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT05319912Written as ALXN1840 Enteric-coated Tablet
- A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy AdultsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT05319899Written as ALXN1840
- Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung CancerWithdrawnPhase 1Roswell Park Cancer InstituteNCT00560495Written as ammonium tetrathiomolybdate
- Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease PatientsCompletedPhase 2Alexion Pharmaceuticals, Inc.NCT02273596Written as ALXN1840
- Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung CancerCompletedPhase 1University of RochesterNCT01837329Written as Tetrathiomolybdate
- Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary CirrhosisCompletedPhase 3George BrewerNCT00805805Written as Tetrathiomolybdate
- Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal CarcinomaCompletedPhase 2University of Michigan Rogel Cancer CenterNCT00176800Written as Tetrathiomolybdate (TM)
Codes
What other systems call tetrathiomolybdate · ClinicalTrials.gg INT002731
- MeSH (NLM) C020809tetrathiomolybdateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4V6I63LW1ETIOMOLIBDATE DIAMMONIUMConfirmed FDA, NLM, Wikidata
- Wikidata Q4747310ammonium tetrathiomolybdateConfirmed FDA, NLM, Wikidata
- DrugBank DB17641One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C020809 | tetrathiomolybdate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4V6I63LW1E | TIOMOLIBDATE DIAMMONIUM | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4747310 | ammonium tetrathiomolybdate | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB17641 | — | One source Wikidata |
Also registered as tiomolibdate choline (UNII FD57A79R4P) and tiomolibdate ion (UNII 91U3TGV99T).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.